

Cover Story
Free
By Matthew Bin Han Ong
The proportion of racial and ethnic minority patients in NCI-funded clinical trials has nearly doubled over two decades—from 14% in 1999 to 25% in 2019, according to data from NCI's National Clinical Trials Network and the NCI Community Oncology Research Program.
In Brief
Clinical Roundup


Drugs & Targets


Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Michael Bishop, Nobel-winning cancer researcher, dies at 90
- A new working group will conduct site visits and advise NCAB and NCI director on cancer center grants
- Roy Herbst named director at Dartmouth Cancer Center
- In the era of immunotherapy, response rate alone fails to predict true patient benefit
Regulators must adapt - FDA issues warning letter to ImmunityBio over misleading claims about cancer drug
















